New York Senate Bill S01282

New York 2025-2026 Regular Session

• Introduced: 1/9/25
• Refer: 1/9/25
• Refer: 1/7/26

Caption

Requires health insurance policies to offer full coverage for annual testing for ovarian cancer; requires certain health care providers offer annual testing for ovarian cancer.

Summary

Bill S01282 mandates that health insurance policies in New York provide full coverage for annual testing for ovarian cancer for individuals identified as high-risk. This includes a variety of testing methods such as FDA-approved testing, transvaginal ultrasounds, and pelvic exams, regardless of whether the patient presents any signs or symptoms. The bill also requires healthcare providers, including physicians and nurse practitioners, to offer these tests and provide educational materials about ovarian cancer to patients. The costs associated with this testing will not be subject to annual deductibles or coinsurance, placing the financial burden solely on insurers.

Impact

If enacted, this bill will significantly alter the landscape of health insurance coverage in New York by ensuring that individuals at high risk for ovarian cancer receive necessary testing without financial barriers. It will amend existing insurance laws and public health regulations, creating a new requirement for insurers and healthcare providers to prioritize ovarian cancer testing and education. This could lead to earlier detection of ovarian cancer, potentially improving health outcomes for affected individuals.

Sentiment

The sentiment surrounding Bill S01282 appears to be generally supportive, as it addresses a critical health issue affecting women. Advocates for women's health and cancer awareness have expressed approval of the bill's intent to enhance access to necessary medical testing. However, there may also be concerns from insurance companies regarding the financial implications of mandated coverage.

Contention

Notable points of contention may arise from insurance providers who could argue that the requirement for full coverage without deductibles or coinsurance may lead to increased costs for them. Additionally, there may be discussions about the adequacy of the current healthcare infrastructure to handle the increased demand for testing and education on ovarian cancer. Some healthcare providers might also raise concerns about the practicality of implementing the mandated educational components.